Mineralys Therapeutics (Nasdaq: MLYS) reported equity inducement awards granted under its 2025 Employment Inducement Incentive Award Plan to new non-executive employees, in line with Nasdaq Listing Rule 5635(c)(4). On July 17 and July 20, 2026, the Compensation Committee approved stock options over a total of 42,800 shares and restricted stock unit (RSU) awards over 32,100 shares of common stock. The options vest monthly over four years after a one-year cliff, while the RSUs vest in four equal annual installments from vesting commencement dates of July 13 and July 20, 2026, contingent on continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Historical reactions included 7.47% after a conference notice and -13.14% after financing-related di...
Analysis
Historical reactions included 7.47% after a conference notice and -13.14% after financing-related disclosures, showing varied event sensitivity. This announcement adds employee equity awards; recent Net Selling is a relevant risk context to monitor.
Key Figures
Stock option award:14,880 sharesRestricted stock unit award:11,160 sharesStock option award:27,920 shares+5 more
8 metrics
Stock option award14,880 sharesNew non-executive employee; granted July 17, 2026
Restricted stock unit award11,160 sharesNew non-executive employee; granted July 17, 2026
Stock option award27,920 sharesAnother new non-executive employee; granted July 20, 2026
Restricted stock unit award20,940 sharesAnother new non-executive employee; granted July 20, 2026
Option vesting periodFour yearsSubject to continued service
Initial option vesting25%On the first anniversary of the vesting commencement date
Monthly option vesting1/48thFollowing each one-month period thereafter
Restricted stock unit vesting25%On each of the first four anniversaries
Jefferies healthcare conference participation and scheduled corporate presentation
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Historical conference and data-presentation announcements diverged from subsequent price reactions, while both June financing-related events recorded a -13.14% reaction.
"granted an inducement stock option award covering 14,880 shares"
An inducement stock option award is a grant of the right to buy company shares given to a newly hired employee as a recruiting incentive. Think of it like a signing bonus paid in future stock: the recipient earns the ability to buy shares over time, aligning their interests with the company’s performance. Investors care because such awards can dilute existing ownership and create compensation expense that affects profits and share value.
restricted stock unit awardfinancial
"an inducement restricted stock unit award covering 11,160 shares"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that (1) on July 17, 2026, the Compensation Committee of Mineralys’ Board of Directors (the Compensation Committee) granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee, and (2) on July 20, 2026, the Compensation Committee granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to another new non-executive employees.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the options vesting on the first anniversary of the awards’ vesting commencement date, July 13, 2026 and July 20, 2026, respectively, and 1/48th of the total shares underlying the options vesting following each one-month period thereafter, subject to continued service.The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the awards’ vesting commencement date, July 13, 2026, and July 20, 2026, respectively.The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
FAQ
What inducement equity awards did Mineralys Therapeutics (MLYS) grant in July 2026?
Mineralys Therapeutics granted inducement stock options on 42,800 shares and restricted stock units on 32,100 shares of common stock. According to Mineralys, these awards were issued to new non-executive employees under the 2025 Employment Inducement Incentive Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
On what dates did Mineralys Therapeutics (MLYS) approve the July 2026 inducement grants?
The Compensation Committee approved inducement awards on July 17, 2026, and July 20, 2026. According to Mineralys, each approval covered both stock option awards and restricted stock unit awards for new non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan.
How do the Mineralys Therapeutics (MLYS) inducement stock options vest for the July 2026 grants?
The inducement stock options vest over four years, with 25% vesting on the first anniversary of the July 13 or July 20, 2026 vesting commencement dates. According to Mineralys, the remaining shares vest in equal monthly installments thereafter, subject to the employees’ continued service.
What is the vesting schedule for the Mineralys Therapeutics (MLYS) inducement RSU awards granted in July 2026?
The inducement RSU awards vest over four years, with 25% of shares vesting on each of the first four anniversaries of July 13 or July 20, 2026. According to Mineralys, vesting is contingent on the recipients’ continued employment with the company throughout the schedule.
Under which plan were the July 2026 Mineralys Therapeutics (MLYS) inducement awards granted?
The July 2026 inducement stock options and RSUs were granted under the Mineralys 2025 Employment Inducement Incentive Award Plan. According to Mineralys, this plan is used specifically to provide equity awards to new employees as permitted by Nasdaq Listing Rule 5635(c)(4).
Why did Mineralys Therapeutics (MLYS) classify these July 2026 equity grants as inducement awards?
Mineralys classified the grants as inducement awards because they were material to the new non-executive employees entering employment with the company. According to Mineralys, this classification aligns with the conditions of Nasdaq Listing Rule 5635(c)(4) for employment inducement grants.
